Navigation Links
Micromet Closes $40 Million Private Equity Placement
Date:10/3/2008

registration requirements. Micromet, Inc. has agreed to file a registration statement with respect to the shares on or before November 3, 2008. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... critical demand to aid high-risk surgeries. From vital sign monitoring in ICU to ... Intel technology enables surgeon to make real-time clinical decisions with simultaneous access to ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's ... entire waste to energy process and continue to contribute to the sustainability of ... Temarry’s Waste to Energy process has been operating at their Mexico facility, Recicladora ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is ... commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion video ... too quickly to process with the naked eye. , Slow motion sequences ...
Breaking Biology Technology:Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... Advantages for Global Life ... ... today,launched a Foreign Trade Zone (FTZ) Service targeting pharmaceutical and,biotechnology ... Sentry,s current services and creates significant,financial advantages and supply chain ...
... Oral Presentation by Prof. Juerg Nussberger, MD, Today at 9.45am (EST):, ... Reduces Early-Morning and Day-Time Blood Pressure.", The ... ... CYT006-AngQb Excellent Long-Term Safety and Tolerability Profile Confirmed: no, ...
... N.J., Nov. 6 Centocor,Inc., Schering-Plough Corporation, ... an estimated one million patients have now ... necrosis,factor (TNF)-alpha therapy worldwide. In fact, REMICADE ... than all other anti-TNF-alpha agents,combined. REMICADE was ...
Cached Biology Technology:Sentry Logistic Solutions Launches Foreign Trade Zone Service 2Sentry Logistic Solutions Launches Foreign Trade Zone Service 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 2Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 4Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 5Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 6Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 2REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 3REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 5REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 6REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 8REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 9REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 10REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 11REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 12
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
Breaking Biology News(10 mins):Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... older person can attest that aging muscles don't heal like ... fault. A study in the Feb. 17 issue of Nature ... , The study, led by Thomas Rando, MD, PhD, associate ... School of Medicine, built on previous work showing that old ...
... resonance imaging) body scanner in the world will be officially ... February). , The Achieva 3T MR Scanner has been purchased ... researchers to further their studies in a wide range of ... revolutionise the way scanning takes place and means that higher ...
... the Veterans Affairs Greater Los Angeles Healthcare System conducted ... cost-effectiveness of current modern drugs for treating hepatitis B ... in the May 17 Annals of Internal Medicine, the ... Researchers note that a degree of uncertainly exists on ...
Cached Biology News:Young Blood Revives Aging Muscles, Stanford Researchers Find 2Young Blood Revives Aging Muscles, Stanford Researchers Find 3Next Generation Body Scanner Launched By The University Of Manchester 2Next Generation Body Scanner Launched By The University Of Manchester 3UCLA study assesses cost-effectiveness of Hepatitis B drugs 2UCLA study assesses cost-effectiveness of Hepatitis B drugs 3
Alexa Fluor 647 anti-mouse Qa-2...
... essential for hunting and analyzing the ... as EST sequencing projects, microarrays, functional ... is developed for normalization of cDNA ... for directional cloning. While most normalization ...
... acquision and analysis software for ... applications. Contains powerful stimulus generation ... functions including automated waveform feature ... includes many electrophysiology specific functions ...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: